Drugs / StreptInCor
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03998592 | May 2021 → Mar 2022 | rheumatic fever | Butantan Institute | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07078357 Comparator | Oct 2025 → Oct 2027 expected | rheumatic disorder, rheumatic heart disease, vaccinia | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | StreptInCor | “The active component of this vaccine candidate is a synthetic polypeptide named StreptInCor designed to elicit humoral and cell-mediated immune responses.” NCT03998592 ↗1“This is a Phase I/IIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor.” NCT07078357 ↗ |
| Modality | Peptide | “synthetic polypeptide” NCT03998592 ↗ |